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Arrhythmogenic right ventricular cardiomyopathy (ARVC) and Brugada syndrome are dis-
tinct clinical entities which diagnostic criteria exclude their coexistence in individual
patients. ARVC is a myocardial disorder characterized by ﬁbro-fatty replacement of the
myocardium and ventricular arrhythmias. In contrast, the Brugada syndrome has long been
considered a functional cardiac disorder: no gross structural abnormalities can be identiﬁed
in the majority of patients and its electrocardiographic hallmark of coved-type ST-segment
elevation in right precordial leads is dynamic. Nonetheless, a remarkable overlap in clinical
features has been demonstrated between these conditions. This review focuses on this
overlap and discusses its potential causes and consequences.
Keywords: Brugada syndrome, arrhythmogenic right ventricular cardiomyopathy, sudden cardiac death, desmo-
some, sodium channel, structural heart disease
INTRODUCTION
The potential overlap between Brugada syndrome and
arrhythmogenic right ventricular cardiomyopathy (ARVC) has
been subject of heated debate (Martini et al., 2001; Pérez Riera
etal.,2005).Contestedinthisdebatearethemyocardialcondition
and thereby the arrhythmogenic mechanism underlying the Bru-
gadasyndrome.Thisreviewwilldescribedtheclinicalfeaturesand
explore the overlap of these features between these syndromes.
ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHY
Marcus et al. (1982) published a case series that for the ﬁrst time
capturedtheclinicalproﬁleofARVC.In24patients,theydescribed
the ﬁbro-fatty replacement,the ventricular tachyarrhythmias,and
premature ventricular complexes with left bundle branch block
morphology, the repolarization abnormalities in the form of
inversed T-waves in the right precordial leads, delayed activation
on standard or signal averaged ECGs, the morphological features
of increased dimensions and wall motion abnormalities of the
right ventricle and the familial occurrence of this disorder. The
causative mechanism was unknown and was speculated to lie
in the development of the right ventricle hence it was termed
“arrhythmogenicrightventriculardysplasia”(Marcusetal.,1982).
Since,our understanding of the causative mechanism of ARVC
has progressed substantially. An important step was made by
the association of ARVC with mutations in the genes encod-
ing the desmosomal proteins plakoglobin (McKoy et al., 2000),
desmoplakin (Rampazzo et al.,2002),plakophilin-2 (Gerull et al.,
2004), desmoglein-2 (Pilichou et al., 2006), and desmocollin-2
(Heuser et al.,2006). These proteins are located at the intercalated
diskinadheringjunctions,whichintheheartcontainbothdesmo-
somal and fascia adherens components, and provide mechanical
strength to the cell–cell junction (Borrmann et al., 2006; Franke
et al., 2006). Mechanical overload of the cell–cell junction is con-
sidered to trigger the pathophysiological myocardial changes in




been substantiated further by mouse models of ARVC (Garcia-
Gras et al., 2006; Kirchhof et al., 2006; Pilichou et al., 2009).
Consistentwiththeconceptofmechanicaloverloadofthecell–cell
junctions, the development of cardiomyopathy in mouse models
can be inﬂuenced by altering the mechanical load on the heart:
endurance training accelerates (Kirchhof et al., 2006) and phar-
macological therapy that lowers the hemodynamic load slows the
development of the ARVC phenotype in heterozygous plakoglo-
bin deﬁcient mice (Fabritz et al., 2011). Indeed, ARVC patients
engagedinendurancetrainingappeartohaveamoresevereARVC
phenotype than those that are not (Sen-Chowdhry et al., 2007b).
The mutations associated with ARVC have been incorpo-
rated in the revised diagnostic Task Force Criteria as pub-
lished in 2010 (Marcus et al., 2010). These diagnostic cri-
teria are divided in six categories: depolarization/conduction
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Table 1 | Revised task force criteria for arrhythmogenic right ventricular cardiomyopathy.
DEPOLARIZATION/CONDUCTIONABNORMALITIES
Major Epsilon wave (V1, V2, or V3)
Minor Signal averaged ECG in the absence of QRSD >110 ms
fQRS duration >114 ms or
Duration of terminal QRS <40μV ≥38ms or
Root-mean-square voltage of terminal 40ms ≤20μV
Terminal activation delay ≥55ms
REPOLARIZATIONABNORMALITIES (IN PATIENTS >14YEARS OFAGE)
Major NegativeT-wave in V1, V2, and V3 (without complete RBBB)
Minor NegativeT-wave in V1 and V2 or in V4, V5, or V6 (without complete RBBB)
NegativeT-wave in V1, V2, V3, and V4 with complete RBBB
VENTRICULARARRHYTHMIAS
Major Non-sustained or sustained VT with LBBB pattern with superior axis
Minor Non-sustained or sustained VT with LBBB pattern with inferior or unknown axis
>500 Premature ventricular complexes/24h
IMAGINGTECHNIQUES
Major 2D Echocardiography
Regional RV akinesia, dyskinesia, or aneurysm and
PLAX RVOT >32mm (or PLAX RVOT >19mm/m2)o r
PSAX RVOT >36mm (or PSAX RVOT >21mm/m2)o r
Fractional area change <33%
MRI
Regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and
Ratio of RVEDV to BSA >110ml/m2 (male) or >100ml/m2 (female) or
RV ejection faction <40%
RV angiography
Regional RV akinesia, dyskinesia, or aneurysm
Minor 2D Echocardiography
Regional RV akinesia or dyskinesia and
PLAX RVOT ≥29 to <32mm (or PLAX RVOT ≥16 to <19mm/m2)o r
PLAX RVOT ≥32 to <36mm (or PLAX RVOT ≥18 to <21mm/m2)o r
Fractional area change ≥33 to <40%
MRI
Regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and
Ratio of RVEDV to BSA ≥100 to <110ml/m2 (male) or ≥90 to >100ml/m2 (female) or
RV ejection faction ≥40 to <45%
HISTOLOGY (ENDOMYOCARDIAL BIOPSY FROM RVFWWITH FIBROUS REPLACEMENT)
Major Residual myocytes <60% on morphometric analysis (or <50% estimated)
Minor Residual myocytes 60–75% on morphometric analysis (or 50–65% estimated)
FAMILY HISTORY
Major First degree relative with ARVC according to current task force criteria
First degree relative with pathologically conﬁrmed ARVC (surgery or atopsy)
Pathogenic mutation categorized as associated or probably associated with ARVC
Minor First degree relative with ARVC undetermined whether diagnosis meets current task force criteria
First degree relative with sudden death <35years of age suspected to be related to ARVC
Second degree relative with ARVC according to current task force criteria
Adapted from Marcus et al. (2010). RBBB, right bundle branch block; VT, ventricular tachycardia; LBBB, left bundle branch block; PLAX, parasternal long-axis view;
RVOT, right ventricular outﬂow tract; PSAX, parasternal short-axis view; RVEDV, right ventricular end diastolic volume; BSA, body surface area; RV, right ventricle;
ARVC, arrhythmogenic right ventricular cardiomyopathy.
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abnormalities, repolarization abnormalities, ventricular arrhyth-
mias, right ventricular structural or functional characteristics as
demonstrated by imaging techniques, histological criteria, and
familial occurrence of ARVC or presence of mutations associated
or probably associated with ARVC (Table 1). In each category,
a major or minor criteria can be scored. A deﬁnite diagnosis of
ARVC is made in the presence of two major, one major and two
minor or four minor criteria. The presence of one major and one
minor or three minor criteria is classiﬁed as“borderline”and one
major or two minor criteria as“possible”diagnosis of ARVC.
THE BRUGADA SYNDROME
BrugadaandBrugada(1992)introducedanewclinicalentitychar-
acterized by right precordial ST-segment elevation followed by a
negative T-wave and sudden cardiac arrest by ventricular ﬁbril-
lation in otherwise healthy individuals. No underlying cause of
the arrhythmias in the form of electrolyte disturbances,coronary,
or structural heart disease could be identiﬁed in these now called
Brugada syndrome patients.
The characteristic electrocardiographic feature (Brugada ECG
pattern) is dynamic and can even disappear temporarily (Bru-
gada and Brugada, 1997). Prior to the initiation of ventricular
ﬁbrillation however, the Brugada ECG pattern reappears in these
patients (Kasanuki et al.,1997). The Brugada ECG pattern is most
pronounced at night or at rest (Mizumaki et al., 2004), during
febrile illness (Amin et al., 2008), and after consumption of a
copious meal (Ikeda et al., 2006) which also are known triggers
of ventricular tachyarrhythmias and sudden death in Brugada
syndrome patients (Matsuo et al., 1999; Ikeda et al., 2006; Amin
et al., 2008; Takigawa et al., 2008). Furthermore, pharmacological
agentshavebeendemonstratedtomodulatetheBrugadaECGpat-
tern. Sodium channel blockers are known to augment or provoke
the Brugada ECG pattern (Miyazaki et al., 1996). Other drugs
can ameliorate the Brugada ECG pattern such as isoproterenol
(Miyazakietal.,1996)andquinidine(Alingsetal.,2001)andhave
beenusedtopreventarrhythmiasinobservationalstudiesandcase
reports (Tanaka et al., 2001; Belhassen et al., 2004). These ﬁnd-
ings suggested the Brugada syndrome to be a functional electrical
cardiac disorder (Ackerman et al.,2011).
Thus far, mutations in 11 genes have been associated with
the Brugada syndrome. Most of these mutations reduce the car-
diac sodium current (INa) and are located in SCN5A (Chen
et al., 1998), the gene encoding the cardiac sodium channel,
its β-subunits SCN1B (Watanabe et al., 2008) and SCN3B (Hu
et al., 2009)o ri nGPD1L (London et al., 2007) and MOG1
(Kattygnarath et al., 2011) which are thought to impair traf-
ﬁcking of the cardiac sodium channel to the cell membrane.
Other mutations associated with the Brugada syndrome reduce
the L-type calcium current (ICaL) and are located in CACNA1C,
CACNB2b (Antzelevitch et al., 2007) and CACNA2D1 (Burash-
nikov et al., 2010) which encode the α1-, β2b-, and α2δ-subunit
of the L-type calcium channel. Lastly, mutations in KCNE3
which encodes MiRP2, a β-subunit of several potassium channels
(Delpon et al., 2009), and in KCNJ8 encoding the ATP-sensitive
potassiumchannel(Barajas-Martínezetal.,2012)havebeenasso-
ciated with the Brugada syndrome. These mutations have been
suggested to increase repolarizing currents activated early during
the action potential (Delpon et al., 2009; Barajas-Martínez et al.,
2012).
The role these mutations play in the Brugada syndrome is sub-
ject of debate. The most common of these mutations appear to be
located in SCN5A which can be identiﬁed in ∼25% of Brugada
syndrome patients (Probst et al.,2010). Even in these patients,the
role of loss-of-function mutations in SCN5A a p p e a r st ob em o r e
complex than that of a dominant mutation with incomplete pen-
etrance. In families affected by the Brugada syndrome in which
theindexpatientcarriedamutationinSCN5A,asigniﬁcantnum-
ber of Brugada syndrome patients (∼1 in 8) does not carry the
mutation in SCN5A (Probst et al.,2009; Santos et al.,2012).




OVERLAPPING FEATURES BETWEEN BRUGADA SYNDROME
AND ARVC
As apparent from the diagnostic criteria, Brugada syndrome and
ARVC are distinct clinical entities with a different scope of clinical
features. Nonetheless, a remarkable number of publications have
shown that features of both syndromes occur in conjunction in
some patients.
BRUGADA SYNDROME FEATURES IN ARVC PATIENTS
Prior to the introduction of the Brugada syndrome, Martini et al.
(1989) presented a patient with right precordial ST-segment ele-
vationandidiopathicventricularﬁbrillation.Onepatientdemon-
stratedwhatwaslatertobecalledtheBrugadaECGpattern.Care-
ful clinical re-evaluation demonstrated enlargement of the right
ventricularoutﬂowtractandrightventricularwallmotionabnor-
malities. This caused the authors to conclude that a concealed
formof ARVCwaspresentinthispatient.Since,morehistological
Table 2 | Diagnostic criteria of Brugada syndrome.
Brugada ECG pattern spontaneous or drug-induced >1 precordial lead and
(Signs of) ventricular tachyarrhythmias in the patient or his/her family
Documented ventricular ﬁbrillation or polymorphic VT or
Syncope or nocturnal agonal breathing or
Inducibility of VT/VF with programmed electrical stimulation or
Family history of sudden cardiac death <45years of age or
Family history of the Brugada ECG pattern without
Confounding factors and factors accounting for the Brugada ECG pattern or
syncopes
Electrocardiographic phenomena that can mimic the Brugada ECG
pattern or
Electrolyte disturbances or hypothermia or
Conditions with ST-segment elevation: pericarditis, myocardial ischemia,
pulmonary embolism or
Structural heart disease such as ARVC or
Miscellaneous
Adapted from Antzelevitch et al. (2005).VT, ventricular tachycardia;VF , ventricular
ﬁbrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy.




(2001) and consisted of 13 young sudden cardiac death victims
with a Brugada ECG pattern on their last recorded ECG. Of these
patients,12 demonstrated structural heart disease consistent with
ARVC at autopsy. Similar to Brugada syndrome patients (Matsuo
et al., 1999), most of these patients died at night or at rest (Tada
et al., 1998; Corrado et al., 2001). Furthermore, polymorphic VTs
asobservedintheBrugadasyndromewererecordedinsomethese
ARVC patients (Corrado et al., 2001).
Secondly, sodium channel blockers can induce the Brugada
ECG pattern ∼1 in 6 patients previously diagnosed with ARVC
(Peters et al., 2004; Peters, 2008). These data indicate the Brugada
ECG pattern, the associated ventricular arrhythmias are present
and can be modulated by INa in some ARVC patients.
ARVC FEATURES IN BRUGADA SYNDROME PATIENTS
Diagnostic ARVC criteria (Marcus et al., 2010) have vice-versa
been demonstrated in Brugada syndrome patients. Thus far,
the diagnostic criteria of ARVC have been validated to dis-
tinguish ARVC from idiopathic right ventricular outﬂow tract
tachycardias (Nasir et al., 2004; Cox et al., 2008) but not from
Brugada syndrome.
Ventricular activation abnormalities in the Brugada syndrome
arewellknown(Postemaetal.,2010).Thusfar,Letsasetal.(2011)
published the only paper that described the presence of electro-
cardiographic ARVC criteria in Brugada syndrome patients in the
absence of sodium channel blockers. Epsilon waves appear to be
rare in Brugada syndrome patients and were found in 2 of 47
patients.Otherconductionabnormalitiesappeartobemorecom-
mon with 40% demonstrating terminal activation delay >55ms
(Letsas et al., 2011). Late potential on signal averaged ECG also
appeartobecommoninBrugadasyndromepatientsandcouldbe
identiﬁed by Ikeda et al. (2001) in the majority of patients despite
using more restrictive cut-off values than the revised Task Force




rare in Brugada syndrome patients (Krittayaphong et al., 2003).
Ventricular arrhythmias therefore, are unlikely to cause suspicion
of ARVC in Brugada syndrome patients.
Imaging studies have revealed moderate structural abnormali-
ties in Brugada syndrome patients despite exclusion of structural
heart disease in the process of diagnosing the Brugada syndrome.
Magnetic resonance imaging (MRI) in 20 Brugada syndrome
patients demonstrated a larger right ventricular outﬂow tract
area compared with control subjects and a high intramyocardial
T1 signal suggestive for fatty inﬁltration in 4 patients (Papavas-
siliu et al., 2004). A more elaborate MRI study also identiﬁed
right ventricular wall motion abnormalities and increased right
ventricular end-systolic and inﬂow tract diameters in Brugada
syndrome patients (Catalano et al., 2009). The structural and
functional abnormalities on MRI appear to be more outspoken
in patients with spontaneous than a drug-induced Brugada ECG
pattern(Papavassiliuetal.,2010).Rightventricularangiographyis
rarelyusedinthework-upofBrugadasyndromepatients,however
microaneurysms during angiography were identiﬁed by Frustaci
et al. (2005) in 7 out of 18 patients undergoing RV endocardial
biopsy.
Thus far, three studies systematically analyzed endocardial
biopsies of Brugada syndrome patients (Frustaci et al., 2005;
Zumhagen et al., 2009; Ohkubo et al., 2010). These studies pro-
ducedvariedﬁndings.Inaseriesof septalrightandleftventricular
biopsies1outof 18patientwasconsistentwithARVCintheseries
by Frustaci et al. (2005) The biopsies in other patients demon-
stratedlymphocyticinﬁltrationin14andhypertrophyanddiffuse
vacuolization in 3 patients. No microaneurysms during right ven-
tricular angiography or signs of myocarditis in endocardial biop-
sies from multiple RV locations were detected by Zumhagen et al.
(2009) However, mild myocardial abnormalities were detected in
endocardial biopsies of most patients. These changes consisted
of hypertrophy, fatty replacement, or ﬁbrosis. The combination
of fatty replacement and ﬁbrosis as required for the diagnosis
of ARVC, was present in 2 patients (Zumhagen et al., 2009). A
biopsy series from Japan, 5 out of 25 patients moderate to severe
fatty replacement was present in RV septal biopsies which were
accompanied by ﬁbrosis in 4 patients (Ohkubo et al.,2010).
Mutations in genes associated with ARVC appear to be rare
in Brugada syndrome patients. No mutations in the gene encod-
ing plakophilin-2, the gene most commonly involved in ARVC
(Kapplingeretal.,2011),couldbeidentiﬁedinscreeningof38Bru-
gadasyndromepatientsinwhomSCN5Awerepreviouslyexcluded
(Koopmann et al., 2007).
POTENTIAL CAUSES OF THE OVERLAPPING FEATURES
BETWEEN BRUGADA SYNDROME AND ARVC PATIENTS
Arrhythmogenic right ventricular cardiomyopathy and Brugada
syndrome show an overlap: (1) the Brugada ECG pattern and the
associated polymorphic VTs are present or can be provoked by
sodium channel blockers in a subgroup of ARVC patients and (2)
three of the diagnostic categories of the Task Force Criteria of
ARVC namely conduction abnormalities,wall motion abnormali-
tiesandhistologyof therightventriclearepresentinBrugadasyn-
drome patients. The question arises at what level these conditions
interact.
Firstly,these syndromes could interact at a genetic level. Muta-
tions in genes associated with ARVC patients could cause electro-
physiological changes that facilitate the pathophysiological mech-
anism of the Brugada syndrome. Support for this hypothesis
can be found in cellular models of reduced mechanical cou-
pling of cardiomyocytes. The adhering junctions, cardiac sodium
channels and gap-junctions, responsible for the electrical cou-
pling between cardiomyocytes, colocalize at the intercalated disk.
Mechanicalstabilityoftheintercalateddiskisthoughttobeimpor-
tantforthefunctionofcardiacsodiumchannelsandgap-junctions
(Delmar and McKenna, 2010). In cultured neonatal rat ventric-
ular myocytes a reduction in the expression of plakophilin-2 is
associated with a reduction in the INa (Sato et al., 2009) and
electrical coupling (Oxford et al., 2007). However, no indica-
tions of altered INa characteristics could be found recently in a
murine model of heterozygous desmoplakin knockout (Gomes
et al.,2012). Reversely,loss-of-function in SCN5A associated with
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Brugada syndrome may predispose patients to develop structural
myocardial derangements as observed in ARVC. Support for such
an hypothesis can be found in heterozygous SCN5A-knockout
mice which develop cardiac ﬁbrosis upon aging (Royer et al.,
2005). The mechanism by which the reduced expression of the
cardiacsodiumchannelcausesﬁbrosisiscurrentlyunknown.Tox-
icity studies with the sodium channel blocker ﬂecainide question
whethertheobservedcardiacﬁbrosisisthedirectresultof reduced
INa. Long-term treatment with ﬂecainide did not result in cardiac
ﬁbrosisinmiceandwasevenassociatedwithareducedprevalence
of cardiac ﬁbrosis in rats (Case et al., 1984). It is therefore uncer-
tain whether these observations in cellular or mouse models can
be extrapolated to man. In case these mechanisms are operational
inman,interactionatageneticlevelisunlikelytofullyaccountfor
the overlap between ARVC and Brugada syndrome. As indicated
above, no mutations in the gene encoding plakophilin-2 could be
identiﬁedinscreeningof Brugadasyndromepatients(Koopmann
et al., 2007) and a mutation in SCN5A could be identiﬁed in only
1 out of 17 ARVC patients with a drug-induced Brugada ECG
pattern (Peters, 2008). Furthermore, structural abnormalities in
Brugadasyndromepatientscouldalsobeidentiﬁedintheabsence
of SCN5A mutations(Frustacietal.,2005;Zumhagenetal.,2009).
Secondly, the electrophysiological mechanism of the Bru-
gada syndrome could cause structural derangements. Support for
this hypothesis can be found in MRI studies. Right ventricular
derangements are more outspoken in patients with a spontaneous
than those with a drug-induced Brugada ECG pattern (Papavas-
siliu et al., 2010). Patients with a spontaneous Brugada ECG pat-
ternareknowntobeatincreasedriskof arrhythmicevents(Probst
etal.,2010).Onecouldthereforealsoarguethatpatientswithmore
structural derangements are more severely affected and are more
likely to demonstrate a spontaneous Brugada ECG pattern. The
fact that sodium channel blockers can provoke the Brugada ECG
pattern in someARVC patients indicate that the electrophysiolog-
ical mechanism depends on structural derangements and not the
other way around (Peters et al.,2004).
Thirdly, structural abnormalities could facilitate the develop-
ment of the Brugada syndrome and that the structural abnor-
malities inherent to ARVC underlie its overlap with the Brugada
syndrome. Thus far, two hypotheses of the pathophysiological
mechanism of the Brugada syndrome have been coined. One
suggests that that a functional change causes subepicardial abbre-
viation of action potential (“repolarization hypothesis”; Yan and
Antzelevitch, 1999), while the other suggest that a structural
change in the subepicardium causes conduction abnormalities
that lead to activation delay (Coronel et al., 2005) or excitation
failure (Hoogendijk et al., 2010a; “depolarization hypothesis”)
underlies the Brugada syndrome. Both hypotheses account for
the modulation of the Brugada syndrome by pharmacological or
genetically determined changes in the INa (Miyazaki et al., 1996;
Chen et al., 1998; London et al., 2007; Watanabe et al., 2008; Hu
et al., 2009; Kattygnarath et al., 2011), ICaL (Miyazaki et al., 1996;
Antzelevitch et al., 2007; Burashnikov et al., 2010), and transient
outwardcurrent(Ito;Alingsetal.,2001;Delponetal.,2009).Inthe
repolarizationhypothesis,thebalanceduringphase-1oftheaction
potential between depolarizing (INa and ICaL) and repolarizing
(Ito) inﬂuence the action potential shortening and ST-segment
similarly as in Brugada syndrome patients (Yan and Antzelevitch,
1999). In the depolarization hypothesis, regional activation delay
in structural discontinuous myocardium make conduction sensi-
tivetocurrentsactivatedaftertheupstrokeof theactionpotential.




Testing of these hypothesis has been troublesome because of
the epicardial localization of the arrhythmogenic substrate in the
Brugada syndrome. Until recently measurements were limited to
electrograms recorded through the conus artery which runs over
the right ventricular outﬂow tract (Shimizu et al., 2001; Nagase
etal.,2002,2008),monophasicactionpotentialsduringopenchest
surgery (Kurita et al., 2002), and a rare explanted heart in the set-
ting of cardiac transplantation (Coronel et al., 2005). None of
these studies was able to demonstrate ST-segment elevation in
local electrograms underlying the Brugada ECG pattern. Recently,
Nademanee et al. (2011) did demonstrate ST-segment elevation
in unipolar electrograms in an epicardial mapping and ablation
studyinninehighlysymptomaticBrugadasyndromepatients.The
ST-segment elevation in unipolar electrograms strongly resem-
bled the Brugada EGG pattern. These electrograms were located
at low-voltage areas with fractionated activation that markedly
exceeding the QRS complex. Ablation at these sites resulted in a
marked reduction in arrhythmic events and disappearance of the
Brugada ECG pattern in eight out of nine patients. Morpholog-
ically identical unipolar electrograms were previously provoked
by sodium channel blockade in the explanted heart of a SCN5A
mutation carrier at sites were the subepicardium was interspersed
byﬁbrousandadiposetissue(Hoogendijketal.,2010a).However,
nodataareavailableonasymptomaticBrugadasyndromepatients
and the mechanism underlying the Brugada syndrome is still at
debate.
CONSEQUENCES OF THE OVERLAPPING FEATURES OF ARVC
AND BRUGADA SYNDROME
In conclusion, the clinical features of Brugada syndrome and
ARVC coincide frequently in patients. The recent publication
of the ﬁrst epicardial electrograms underlying the Brugada ECG
pattern support the notion that conduction disturbances in struc-
tural discontinuous myocardium underlie the Brugada syndrome
(Hoogendijk et al., 2010a; Nademanee et al., 2011). The struc-
turalrightventricularabnormalitiesinARVCthereforemostlikely
predispose patients to develop the Brugada ECG pattern and the
associatedventriculararrhythmias(Hoogendijketal.,2010b).The
strict exclusion of structural heart disease in the Brugada syn-
drome as advocated in the 2005 consensus report (Antzelevitch
etal.,2005)appeararbitrary.Theseconclusionspleadforabroad-
ening of the diagnostic criteria by making a distinction in patients
with the Brugada features in the presence and absence (Brugada
syndrome) of identiﬁable underlying structural heart disease.
The treatment of these patients with the Brugada features in
the setting of structural heart disease remains challenging. The
arrhythmogenic risk in these patients has not been clearly estab-
lished and may prove to be difﬁcult to determine in the future.
First of all, this patients group is heterogeneous and incorporates
www.frontiersin.org May 2012 | Volume 3 | Article 144 | 5Hoogendijk ARVC and Brugada syndrome
various underlying cardiac conditions besides ARVC (Corrado
etal.,1996,2001;Tadaetal.,1998;Petersetal.,2004):theBrugada
ECGpatterncanalsooccurinthesettingofChagas’disease(Chiale
et al.,1982; Brito et al.,2010). Thus far,prospective data are avail-
able of only 17 ARVC patients with drug-induced Brugada ECG
(Peters, 2008) which is associated with a low arrhythmogenic risk
in the setting of Brugada syndrome (Probst et al.,2010). Only one
monomorphic ventricular was recorded during follow-up (Peters,
2008). Secondly, the myocardial condition and arrhythmogenic
substratethatfacilitatestheBrugadafeaturesmaychangeovertime
in patients with and underlying cardiomyopathy. In the ARVC
follow-up study by Peters, the reproducibility of drug-induced
Brugada ECG pattern was four out of eight (Peters, 2008). Until
the arrhythmogenic risk in patients with the Brugada ECG pat-
tern in the setting of structural heart disease has been assessed, it
appears reasonable to avoid or treat known triggers arrhythmias
in Brugada syndrome patients such as certain pharmacological
agents (Postema et al., 2009) and fever (Amin et al.,2008).
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